135 related articles for article (PubMed ID: 38613465)
1. Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2-related factor 2 (Nrf2).
Wang X; Yang J; Li D; Teng L; Chen Y; Meng J; Yang C; Yin Z; Li C
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23689. PubMed ID: 38613465
[TBL] [Abstract][Full Text] [Related]
2. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
Amaro F; Pisoeiro C; Valente MJ; Bastos ML; Guedes de Pinho P; Carvalho M; Pinto J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077297
[TBL] [Abstract][Full Text] [Related]
4. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
Huang H; Wu Y; Fu W; Wang X; Zhou L; Xu X; Huang F; Wu Y
Int J Mol Med; 2019 May; 43(5):2044-2054. PubMed ID: 30896860
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
Zhu Y; Xu L; Zhang J; Hu X; Liu Y; Yin H; Lv T; Zhang H; Liu L; An H; Liu H; Xu J; Lin Z
Cancer Sci; 2013 Aug; 104(8):1052-61. PubMed ID: 23578198
[TBL] [Abstract][Full Text] [Related]
7. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
8. The protective effects of Chromofungin in oligomeric amyloid β
Li Q; Sun J; Ran Q; Liu Z; Chen J
Aging (Albany NY); 2024 May; 16(10):9216-9227. PubMed ID: 38795392
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rh4 Facilitates the Sensitivity of Renal Cell Carcinoma to Ferroptosis via the NRF2 Pathway.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Mar; 77(2):119-128. PubMed ID: 38583003
[TBL] [Abstract][Full Text] [Related]
10. Neratinib stimulates senescence of mammary cancer cells by reducing the levels of SIRT1.
Li W; Fu P; Shi P; Hu B; Li H
Aging (Albany NY); 2024 May; 16():. PubMed ID: 38829772
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
12. Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
Wang P; Wang P; Luan H; Wu Y; Chen Y
Brain Behav; 2023 Jan; 13(1):e2822. PubMed ID: 36444490
[TBL] [Abstract][Full Text] [Related]
13. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells.
Jones KR; Elmore LW; Jackson-Cook C; Demasters G; Povirk LF; Holt SE; Gewirtz DA
Int J Radiat Biol; 2005 Jun; 81(6):445-58. PubMed ID: 16308915
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine accelerates senescence of endothelial cells via DNA hypomethylation of human telomerase reverse transcriptase.
Zhang D; Sun X; Liu J; Xie X; Cui W; Zhu Y
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):71-8. PubMed ID: 25359865
[TBL] [Abstract][Full Text] [Related]
15. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
17. Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes.
Huang Z; Lan J; Gao X
ACS Omega; 2021 Apr; 6(14):9442-9448. PubMed ID: 33869924
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
[TBL] [Abstract][Full Text] [Related]
19. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Sternberg CN; Davis ID; Mardiak J; Szczylik C; Lee E; Wagstaff J; Barrios CH; Salman P; Gladkov OA; Kavina A; Zarbá JJ; Chen M; McCann L; Pandite L; Roychowdhury DF; Hawkins RE
J Clin Oncol; 2010 Feb; 28(6):1061-8. PubMed ID: 20100962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
